International Journal of Alzheimer’s Disease / 2013 / Article / Tab 2

Research Article

Preferential Selectivity of Inhibitors with Human Tau Protein Kinase Gsk3 Elucidates Their Potential Roles for Off-Target Alzheimer’s Therapy

Table 2

Percentage identity, similarity, and RMSD values (for the overlapping number of atoms).

GSK3βCDK5P38ERK1/2JNKCK1dDYRK1AAKTPKA

CDK5 #35.6%
@66.0%
*1.25 (238)
P3832.3%
62.0%
*1.45 (221)
36.4%
64.9%
*1.52 (202)
ERK1/232.8%
64.5%
*1.43 (252)
37.6%
68.0%
*1.42 (233)
49.0%
77.4%
*1.60 (277)
JNK28.0%
54.8%
*1.59 (238)
35.4%
64.3%
*1.61 (228)
47.7%
75.3%
*1.65 (265)
43.1%
73.8%
*1.46 (287)
CK1d25.3%
49.6%
*1.64 (205)
22.8%
48.1%
*1.60 (200)
25.6%
54.0%
*1.72 (167)
29.5%
50.4%
*1.75 (195)
24.6%
50.8%
*1.76 (188)
DYRK1A28.4%
53.2%
*1.29 (253)
30.4%
7.5%
*1.34 (243)
29.1%
53.6%
*1.52 (218)
28.3%
57.1%
*1.39 (246)
28.9%
52.3%
*1.72 (247)
24.5%
51.8%
*1.57 (213)
AKT27.0%
48.4%
*1.55 (222)
25.4%
57.4%
*1.47 (214)
26.1%
56.7%
*1.61 (205)
22.8%
53.1%
*1.48 (231)
26.3%
52.5%
*1.64 (221)
25.8%
54.5%
*1.68 (207)
26.0%
56.4%
*1.36 (230)
PKA26.4%
59.2%
*1.56 (213)
23.4%
58.9%
*1.50 (207)
26.6%
59.4%
*1.65 (183)
24.1%
53.9%
*1.65 (214)
26.3%
52.9%
*1.72 (194)
26.1%
53.8%
*1.76 (207)
26.0%
57.1%
*1.50 (219)
45.6%
77.2%
*1.21 (292)
PKC24.8%
51.8%
*1.52 (223)
27.8%
61.9%
*1.45 (214)
27.9%
56.4%
*1.65 (203)
23.9%
56.2%
*1.68 (228)
24.6%
50.8%
*1.82 (221)
23.5%
55.8%
*1.70 (208)
25.9%
56.7%
*1.43 (224)
47.4%
79.2%
*1.07 (285)
32.8%
60.3%
*1.37 (279)

Identity, @similarity, and *RMSD (total number of atoms involved).

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19.